Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Immunoaffinity purification of factor VIII.

R E Weinstein¹

¹Division of Hematology/Oncology, University of Connecticut Health Center, Farmington 06032.

Annals of Clinical and Laboratory Science

|March 1, 1989

Summary

New factor VIII concentrates purified using monoclonal antibodies (mAb) significantly improve hemophilia care by reducing viral contamination and foreign proteins. These advanced treatments offer enhanced safety and efficacy for patients with hemophilia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Decreased adrenal sex steroid levels in the absence of glucocorticoid suppression in postmenopausal asthmatic women.

The Journal of allergy and clinical immunology·1996

Same author

Recurrent venous thrombosis as the presenting manifestation of acute lymphocytic leukemia: leukemic cell procoagulant activity is not responsible for the hypercoagulable state.

Medical and pediatric oncology·1995

Same author

Allergy and the Geschwind-Behan-Galaburda model.

Brain and cognition·1994

Same author

Effect of rabbit activated protein C on thrombin generation and fibrinolysis in a species-specific in vivo model: effect of modulation of protein S activity.

Seminars in thrombosis and hemostasis·1993

Same author

The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S.

The American journal of medicine·1992

Same author

Altered cerebral dominance in atopy and in children of asthmatic mothers.

Annals of the New York Academy of Sciences·1992

Area of Science:

Hematology
Immunology
Biotechnology

Background:

Traditional factor VIII concentrates pose risks of immunologic abnormalities and viral transmission (HIV, hepatitis) in hemophilia patients.
Factor VIII and von Willebrand factor (vWF) are complexed in plasma, necessitating advanced purification techniques.
Previous methods resulted in high levels of contaminants, impacting patient safety and treatment outcomes.

Purpose of the Study:

To evaluate the safety and efficacy of immunoaffinity-purified factor VIII concentrates.
To compare purification methods utilizing monoclonal antibodies (mAb) against factor VIII or vWF.
To assess the reduction in viral risk and foreign protein content in novel factor VIII concentrates.

Main Methods:

Immunoaffinity purification of factor VIII using monoclonal antibodies (mAb) immobilized on a solid support.
Commercial-scale production of factor VIII concentrates (Monoclate, Hemophil M) employing different mAb targets.
Implementation of viral purification and inactivation procedures during concentrate manufacturing.

Main Results:

Purified factor VIII concentrates exhibit significantly higher purity compared to traditional preparations.
Both Monoclate and Hemophil M demonstrate reduced viral contamination and foreign protein load.
Early clinical studies indicate effectiveness in treating bleeding episodes with a low risk of HIV or hepatitis infection.

Conclusions:

Monoclonal antibody technology provides a superior method for factor VIII concentrate purification.
These advanced concentrates represent a significant advancement in hemophilia care, particularly for previously untransfused individuals.
Further research is needed to clarify the role of these products in managing HIV-infected hemophilia patients.

Related Experiment Videos